144 Chapter 8 Table 1. Clinical trials with antibody-based PD-(L)1 PET-imaging Clinical trial Target Tumor types Radiotracer PD-L1 assessment on fresh/ archival biopsy Correlation PD(L)1 expression Correlation treatment response Bensch et al. Nature comm 218 PD-L1 NSCLC, TNBC, BC [89Zr]Zr-atezolizumab Fresh YES YES Niemeijer et al. Nature comm 2018 PD-1 NSCLC [89Zr]Zr-nivolumab YES YES Niemeijer et al. J. Nucl Med 2021 PD-1 NSCLC [89Zr]Zr-pembrolizumab NO YES? (non-significant) Smit et al. J. Nucl Med 2021 PD-L1 NSCLC [89Zr]Zr-durvalumab Archival? NO YES? (non-significant) Verhoeff et al. J. Nucl Med 2022 PD-L1 SCCHN [89Zr]Zr-durvalumab Fresh & archival NO NO Verhoeff et al. (NCT03514719) PD-L1 NSCLC [89Zr]Zr-avelumab Fresh & archival TBD TBD TBD = to be determined, NSCLC= Non small lung cancer, TNBC = Triple negative breast cancer, BC = bladder cancer, SCCHN = Squamous cell carcinoma of the head and neck
RkJQdWJsaXNoZXIy MTk4NDMw